Business Description
Annovis Bio Inc
NAICS : 325411
SIC : 2833
ISIN : US03615A1088
Share Class Description:
FRA:07X: Ordinary SharesTotal Employee Number:
7Description
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.19 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 22.7 | |||||
3-Year EPS without NRI Growth Rate | 23.1 | |||||
3-Year FCF Growth Rate | 16.2 | |||||
3-Year Book Growth Rate | -43.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -7.39 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 74.23 | |||||
9-Day RSI | 62.74 | |||||
14-Day RSI | 55.8 | |||||
3-1 Month Momentum % | -10.77 | |||||
6-1 Month Momentum % | -45.55 | |||||
12-1 Month Momentum % | -20.1 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.27 | |||||
Quick Ratio | 1.27 | |||||
Cash Ratio | 1.11 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -49.4 | |||||
Shareholder Yield % | -22.55 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -270.95 | |||||
ROA % | -199.22 | |||||
ROIC % | -2355.64 | |||||
ROC (Joel Greenblatt) % | -2355.64 | |||||
ROCE % | -268.16 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 17.55 | |||||
Price-to-Tangible-Book | 16.68 | |||||
EV-to-EBIT | -1.64 | |||||
EV-to-Forward-EBIT | -2.23 | |||||
EV-to-EBITDA | -1.64 | |||||
EV-to-Forward-EBITDA | -0.92 | |||||
EV-to-FCF | -2.56 | |||||
| Price-to-Net-Current-Asset-Value | 16.68 | |||||
| Price-to-Net-Cash | 55.6 | |||||
Earnings Yield (Greenblatt) % | -60.98 | |||||
FCF Yield % | -32.32 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Annovis Bio Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -1.47 | ||
| Beta | 4.9276 | ||
| 3-Year Sharpe Ratio | 0.14 | ||
| 3-Year Sortino Ratio | 0.3 | ||
| Volatility % | 177.48 | ||
| 14-Day RSI | 55.8 | ||
| 14-Day ATR (€) | 0.053629 | ||
| 20-Day SMA (€) | 1.5482 | ||
| 12-1 Month Momentum % | -20.1 | ||
| 52-Week Range (€) | 1.35 - 4.61 | ||
| Shares Outstanding (Mil) | 42.54 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Annovis Bio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Annovis Bio Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 130 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 38 days | ||
| General meeting for 2026 | 2026-06-17 10:00 | 1.56 (+2.90%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 1.99 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-16 | 2.21 (+2.80%) | ||
| Annual report for 2025 | 2026-03-13 | 2.14 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-12 | 1.70 (+0.00%) | ||
| Guidance call for 2025 | 2025-09-10 12:00 | 1.97 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-12 | 2.16 (+0.00%) | ||
| General meeting for 2025 | 2025-06-17 10:00 | 2.41 (+0.00%) |
Show
Entries
Annovis Bio Inc Frequently Asked Questions
What is Annovis Bio Inc(FRA:07X)'s stock price today?
The current price of FRA:07X is €1.67. The 52 week high of FRA:07X is €4.61 and 52 week low is €1.35.
When is next earnings date of Annovis Bio Inc(FRA:07X)?
The next earnings date of Annovis Bio Inc(FRA:07X) is 2026-08-12 Est..
Does Annovis Bio Inc(FRA:07X) pay dividends? If so, how much?
Annovis Bio Inc(FRA:07X) does not pay dividend.
Press Release
Articles on Annovis Bio Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers